Please click "REQUEST A QUOTE" button if there is no stock, or
you need other sizes or custom synthesis.
Catalog:
SLK-S9871
Brand:
Selleck
CAS:
304456-62-0
Overview
MDL
MFCD00977636
Molecular Weight
309.18
Molecular Formula
C12H9BrN2OS
SMILES
O=C(N)C1=CC=CC=C1/N=C/C2=CC=C(Br)S2
For research use only.
Storage
3 years,-20°C,powder 1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
1 mg
5 mg
10 mg
1 mM
3.2344 mL
16.1718 mL
32.3436 mL
5 mM
0.6469 mL
3.2344 mL
6.4687 mL
10 mM
0.3234 mL
1.6172 mL
3.2344 mL
50 mM
0.0647 mL
0.3234 mL
0.6469 mL
Description
BTYNB (BTYNB IMP1 Inhibitor, MDK6620) is a potent and selective inhibitor of binding to mRNA. BTYNB downregulates β-TrCP1 mRNA and reduces activation of . BTYNB disrupts this enhancer function by impairing IGF2 mRNA-binding protein 1 (IGF2BP1)-RNA association.
In cells, BTYNB downregulates several mRNA transcripts regulated by IMP1. BTYNB destabilizes c-Myc mRNA, resulting in downregulation of c-Myc mRNA and protein. BTYNB downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB). The oncogenic translation regulator, eEF2, emerges as a new IMP1 target mRNA, enabling BTYNB to inhibit tumor cell protein synthesis. BTYNB potently inhibits proliferation of IMP1-containing ovarian cancer and melanoma cells with no effect in IMP1-negative cells. Overexpression of IMP1 reverses BTYNB inhibition of cell proliferation. BTYNB completely blocks anchorage-independent growth of melanoma and ovarian cancer cells in colony formation assays.
